Researchers will be looking at a medication that recently received experimental approval from the USDA and its impact on the newly characterized form of dementia known as LATE. LATE is a disease with symptoms similar to Alzheimer’s disease.
For the past several decades, much of the work to find a treatment for AD has been focused on eliminating those dreaded Aβ plaques, by assuming that memory could be restored by removing the plaques.
The National Institutes of Health award will fund ongoing research led by UK Neuroscience and Spinal Cord and Brain Injury Research Center (SCoBIRC) Professor Patrick Sullivan, Ph.D., who has studied the effects of the experimental drug MP201 on TBI.
This work is looking at a study medication, BAN2401, to determine if it can help prevent worsening memory and thinking among individuals who might be at risk for future decline. They are hoping it will ultimately help prevent Alzheimer’s disease.
The $125,000 grant comes from The CART Fund. CART (Coins for Alzheimer’s Research Trust) is a grassroots effort by Rotary Club members throughout the country to provide cutting edge research to help find a cure for Alzheimer’s.
The long-running study on aging and brain health at UK’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.
The work at UK in Gentry’s lab supported by this award will focus on novel insights in energy metabolism using cutting edge methodologies applied to multiple human diseases.
Linda J. Van Eldik, director of the Sanders-Brown Center on Aging at UK, co-authored a paper reporting the first human clinical study of a drug candidate that suppresses injury and disease-induced inflammation of the brain.
When you look back at a 45-year career, there are a multitude of moments that stand out. For Allan Butterfield, Professor of Biological Chemistry in the UK College of Arts & Sciences, his signature discovery grew from just such a Eureka moment on the sidewalk on campus.
“I can’t advocate for someone unless I’m working with them. It’s presumptuous to say, ‘I know what you need,’” Kitzman said. “The moment we at KARRN start working with someone, we agree to be their advocate and do whatever it takes to find resources for them.”
